Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Study

2021 ◽  
Author(s):  
Sarah Buelens ◽  
Filip Poelaert ◽  
Tom Claeys ◽  
Elise De Bleser ◽  
Bert Dhondt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Local Treatment

Multicentric prospective Local treatment of Metastatic Prostate cancer (LoMP) trial: Evaluation of local events

2017 ◽  
Vol 16 (10) ◽  
pp. e2693
Author(s):  
S. Buelens ◽  
F. Poelaert ◽  
B. Dhondt ◽  
C. Verbaeys ◽  
B. Rappe ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Local Treatment

Rationale for local treatment in the management of metastatic prostate cancer

2016 ◽  
Vol 10 (3) ◽  
pp. 266-272 ◽  
Author(s):  
Giorgio Gandaglia ◽  
Nicola Fossati ◽  
Paolo Dell’Oglio ◽  
Marco Moschini ◽  
Vito Cucchiara ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Local Treatment

Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial

Urology ◽  
2017 ◽  
Vol 106 ◽  
pp. 146-152 ◽  
Author(s):  
Filip Poelaert ◽  
Caroline Verbaeys ◽  
Bernard Rappe ◽  
Bart Kimpe ◽  
Ignace Billiet ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Local Treatment ◽  
Lessons Learned

Local Treatment in the Management of Oligometastatic Prostate Cancer

2018 ◽  
Author(s):  
Derya Tilki ◽  
Christopher P Evans
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Metastatic Prostate Cancer ◽  
Randomized Clinical Trials ◽  
Retrospective Studies ◽  
Local Treatment ◽  
Oncologic Outcomes ◽  
Newly Diagnosed ◽  
Oligometastatic Prostate Cancer ◽  
Treatment Paradigm

Oncologic outcomes of patients with newly diagnosed metastatic prostate cancer (mPCa) are poor, with overall survival in the range of 44 to 60 months. The treatment paradigm for newly diagnosed mPCa is changing. Previous retrospective studies reported a survival benefit for local treatment (radical prostatectomy or radiotherapy) in addition to androgen deprivation treatment in the setting of oligometastatic prostate cancer. Several randomized clinical trials are now evaluating integration of local treatment in the approach to mPCa. The aim of this review is to summarize the studies reporting local treatment in men with mPCa at diagnosis. This review contains 1 table and 27 references.  Key Words: cytoreductive prostatectomy, hormone-naive, local treatment, metastatic prostate cancer, oligometastatic, radical prostatectomy, radiotherapy, randomized

MP50-12 THE IMPACT OF LOCAL TREATMENT ON OVERALL MORTALITY IN PATIENTS DIAGNOSED WITH PRIMARY METASTATIC PROSTATE CANCER

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Björn Löppenberg ◽  
Deepansh Dalela ◽  
Patrick Karabon ◽  
Akshay Sood ◽  
Jesse Sammon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Local Treatment ◽  
The Impact ◽  
Overall Mortality

Survival benefit of local vs. no local treatment for metastatic prostate cancer - impact of baseline PSA and metastatic substages

2018 ◽  
Vol 17 (2) ◽  
pp. e1849
Author(s):  
R.S. Pompe ◽  
D. Tilki ◽  
F. Preisser ◽  
S.-R. Leyh-Bannurah ◽  
M. Bandini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Benefit ◽  
Metastatic Prostate Cancer ◽  
Local Treatment ◽  
Baseline Psa
Sign in / Sign up

Export Citation Format

Share Document